Its mutation is mainly associated with the de-repression of pluripotency genes (OCT4 and SOX2) and increased expression of EZH2. Dual inactivation of TP53 and RB1 in mice is a widely used procedure to develop in vivo cancer models similar to human SCLC [11]. This evidence concerns the gene EZH2 and small cell lung carcinoma.